Cargando…

Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials

BACKGROUND: Early study exit is detrimental to statistical power and increases the risk for bias in Alzheimer’s disease clinical trials. Previous analyses in early phase academic trials demonstrated associations between rates of trial incompletion and participants’ study partner type, with participa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernstein, Olivia M., Grill, Joshua D., Gillen, Daniel L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791680/
https://www.ncbi.nlm.nih.gov/pubmed/33419457
http://dx.doi.org/10.1186/s13195-020-00762-8
_version_ 1783633644201443328
author Bernstein, Olivia M.
Grill, Joshua D.
Gillen, Daniel L.
author_facet Bernstein, Olivia M.
Grill, Joshua D.
Gillen, Daniel L.
author_sort Bernstein, Olivia M.
collection PubMed
description BACKGROUND: Early study exit is detrimental to statistical power and increases the risk for bias in Alzheimer’s disease clinical trials. Previous analyses in early phase academic trials demonstrated associations between rates of trial incompletion and participants’ study partner type, with participants enrolling with non-spouse study partners being at greater risk. METHODS: We conducted secondary analyses of two multinational phase III trials of semagacestat, an oral gamma secretase inhibitor, for mild-to-moderate AD dementia. Cox’s proportional hazards regression model was used to estimate the relationship between study partner type and the risk of early exit from the trial after adjustment for a priori identified potential confounding factors. Additionally, we used a random forest model to identify top predictors of dropout. RESULTS: Among participants with spousal, adult child, and other study partners, respectively, 35%, 38%, and 36% dropped out or died prior to protocol-defined study completion, respectively. In unadjusted models, the risk of trial incompletion differed by study partner type (unadjusted p value = 0.027 for test of differences by partner type), but in models adjusting for potential confounding factors, the differences were not statistically significant (p value = 0.928). In exploratory modeling, participant age was identified as the primary characteristic to explain the relationship between study partner type and the risk of failing to complete the trial. Participant age was also the strongest predictor of trial incompletion in the random forest model. CONCLUSIONS: After adjustment for age, no differences in the risk of incompletion were observed when comparing participants with different study partner types in these trials. Differences between our findings and the findings of previous studies may be explained by differences in trial phase, size, geographic regions, or the composition of academic and non-academic sites.
format Online
Article
Text
id pubmed-7791680
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77916802021-01-11 Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials Bernstein, Olivia M. Grill, Joshua D. Gillen, Daniel L. Alzheimers Res Ther Research BACKGROUND: Early study exit is detrimental to statistical power and increases the risk for bias in Alzheimer’s disease clinical trials. Previous analyses in early phase academic trials demonstrated associations between rates of trial incompletion and participants’ study partner type, with participants enrolling with non-spouse study partners being at greater risk. METHODS: We conducted secondary analyses of two multinational phase III trials of semagacestat, an oral gamma secretase inhibitor, for mild-to-moderate AD dementia. Cox’s proportional hazards regression model was used to estimate the relationship between study partner type and the risk of early exit from the trial after adjustment for a priori identified potential confounding factors. Additionally, we used a random forest model to identify top predictors of dropout. RESULTS: Among participants with spousal, adult child, and other study partners, respectively, 35%, 38%, and 36% dropped out or died prior to protocol-defined study completion, respectively. In unadjusted models, the risk of trial incompletion differed by study partner type (unadjusted p value = 0.027 for test of differences by partner type), but in models adjusting for potential confounding factors, the differences were not statistically significant (p value = 0.928). In exploratory modeling, participant age was identified as the primary characteristic to explain the relationship between study partner type and the risk of failing to complete the trial. Participant age was also the strongest predictor of trial incompletion in the random forest model. CONCLUSIONS: After adjustment for age, no differences in the risk of incompletion were observed when comparing participants with different study partner types in these trials. Differences between our findings and the findings of previous studies may be explained by differences in trial phase, size, geographic regions, or the composition of academic and non-academic sites. BioMed Central 2021-01-08 /pmc/articles/PMC7791680/ /pubmed/33419457 http://dx.doi.org/10.1186/s13195-020-00762-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bernstein, Olivia M.
Grill, Joshua D.
Gillen, Daniel L.
Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials
title Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials
title_full Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials
title_fullStr Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials
title_full_unstemmed Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials
title_short Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials
title_sort recruitment and retention of participant and study partner dyads in two multinational alzheimer’s disease registration trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791680/
https://www.ncbi.nlm.nih.gov/pubmed/33419457
http://dx.doi.org/10.1186/s13195-020-00762-8
work_keys_str_mv AT bernsteinoliviam recruitmentandretentionofparticipantandstudypartnerdyadsintwomultinationalalzheimersdiseaseregistrationtrials
AT grilljoshuad recruitmentandretentionofparticipantandstudypartnerdyadsintwomultinationalalzheimersdiseaseregistrationtrials
AT gillendaniell recruitmentandretentionofparticipantandstudypartnerdyadsintwomultinationalalzheimersdiseaseregistrationtrials